Bank Pictet & Cie Europe AG Buys 2,179 Shares of Danaher Co. (NYSE:DHR)

Bank Pictet & Cie Europe AG raised its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 1.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 194,910 shares of the conglomerate's stock after purchasing an additional 2,179 shares during the period. Bank Pictet & Cie Europe AG's holdings in Danaher were worth $39,957,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in DHR. Norges Bank bought a new position in shares of Danaher in the 4th quarter valued at approximately $2,130,740,000. GAMMA Investing LLC grew its holdings in shares of Danaher by 24,958.2% during the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after purchasing an additional 1,863,381 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Danaher during the 4th quarter worth approximately $391,172,000. Two Sigma Advisers LP grew its holdings in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after purchasing an additional 1,601,800 shares in the last quarter. Finally, Capital World Investors boosted its stake in Danaher by 32.7% in the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after buying an additional 1,566,658 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Trading Up 0.2%

Shares of Danaher stock traded up $0.47 during trading on Monday, reaching $201.14. 3,142,903 shares of the company were exchanged, compared to its average volume of 3,489,412. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $171.00 and a twelve month high of $281.70. The business has a 50-day moving average price of $192.80 and a 200-day moving average price of $210.81. The firm has a market capitalization of $143.95 billion, a price-to-earnings ratio of 38.09, a P/E/G ratio of 2.66 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. Danaher's payout ratio is 24.85%.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Argus decreased their price target on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. decreased their price target on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 22nd. Wells Fargo & Company decreased their price target on Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 23rd. Robert W. Baird decreased their price target on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Danaher has an average rating of "Moderate Buy" and an average target price of $248.17.

Insider Buying and Selling at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.